UTRECHT, The Netherlands, and PHILADELPHIA — November 13, 2025 — Leads & Copy —
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that 22,877,463 of its common shares were validly tendered and not withdrawn before the expiration of the initial offering period on November 12, 2025. This represents approximately 87% of LAVA’s outstanding common shares. The company stated that the minimum tender condition and other conditions of the tender offer from XOMA Royalty Corporation to acquire LAVA have been satisfied.
All validly tendered shares are expected to be accepted for payment on or about November 13, 2025. A subsequent offering period has commenced for LAVA shareholders who have not yet tendered their common shares. This period will end one minute after 11:59 p.m. Eastern Time on November 20, 2025. Common shares tendered during this subsequent offering period may not be withdrawn.
LAVA anticipates its common shares will be suspended from trading on the Nasdaq Global Select Market before the market opens on or about November 21, 2025.
LAVA also announced that it has provided written notice to Nasdaq of its intention to voluntarily delist its common shares from the exchange. The delisting is contingent upon XOMA Royalty acquiring all common shares validly tendered and not properly withdrawn, per the purchase agreement between LAVA and XOMA Royalty.
Nasdaq is expected to file a notification with the U.S. Securities and Exchange Commission (SEC) on or about November 24, 2025, regarding the removal of LAVA’s common shares from listing. The completion of the tender offer remains subject to conditions outlined in the tender offer statement on Schedule TO filed by XOMA Royalty with the SEC.
LAVA Therapeutics N.V. is a biopharmaceutical company focused on developing clinical-stage bispecific gamma delta T cell engagers using its Gammabody® platform. These include JNJ-89853413, targeting CD33 and hematologic cancers (NCT06618001), partnered with Johnson & Johnson, and PF-08046052, targeting EGFR and solid tumors (NCT05983133), partnered with Pfizer, Inc.
Fred Powell
LAVA Therapeutics
+1 800-311-6892
ir@lavatherapeutics.com
Gammabody® is a registered trademark of LAVA Therapeutics N.V.
Source: LAVA Therapeutics N.V.
